Search
Levodopa
go.drugbank.com/drugs/DB01235ApprovedInvestigationalLevodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. … Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after
Mixtures: LEVODOPA P BENS AL 100/25, LEVODOPA P BENS AL 100/25Iron Dextran
go.drugbank.com/drugs/DB00893ApprovedInvestigationalVet approvedIron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administ...
Mixtures: Se-Tan DHA, Se-Tan DHAOxaliplatin
go.drugbank.com/drugs/DB00526ApprovedInvestigational[A796,A797] This is an effective combination treatment both as a first-line treatment and in patients refractory to an initial fluorouracil and leucovorin combination. … [A797] Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics.
Milsaperidone
go.drugbank.com/drugs/DB24348ApprovedInvestigational[A275426, A202004] Similarly, milsaperidone acts as an antagonist at dopamine D2 and 5-HT2A receptors,[A275427] as well as other adrenergic, dopamine, and serotonin receptor subtypes. … [L56056] Atypical antipsychotic agents work by blocking the D2 dopamine and serotonin receptor signalling pathways.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesVayarin
go.drugbank.com/drugs/DB09328ApprovedVayarin is an orally administered prescription medical food for the clinical dietary management of complex lipid imbalances thought to be associated with ADHD. … A slow response time of 12 weeks is an impediment to successful management of ADHD as only 41.6% of subjects prescribed Vayarin remained compliant for the duration of the study.
Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme InhibitorsSarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigational[A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersPipradrol
go.drugbank.com/drugs/DB11584ApprovedWithdrawnPipradrol (Meratran) [L2523] was initially developed in the 1950s as an antidepressant, however, the adverse effects associated with its use and its abuse potential led to its withdrawal and international
Naloxone
go.drugbank.com/drugs/DB01183ApprovedInvestigationalVet approvedDue to its short duration of action, persons injected with naloxone should be monitored for responsiveness and potentially injected a second time or taken to the hospital. … However, for individuals using opioid medications or experiencing an overdose, IM injection of naloxone rapidly reverses opioid effects and can cause the injected individual to immediately experience withdrawal
Mixtures: TILIDIN 100/8 RETARD 1A PH, TILIDIN 100/8 RETARD 1A PHCategories: P-glycoprotein substrates, Cytochrome P-450 SubstratesNalbuphine
go.drugbank.com/drugs/DB00844ApprovedInvestigationalIt appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors.
Lutropin alfa
go.drugbank.com/drugs/DB00044ApprovedInvestigationalIts pharmacological action mimics the biological activity of endogenous LH; an acute rise of LH, or LH surge, in females triggers ovulation and the development of the corpous luteum.
Mixtures: PERGOVERIS 150 IU/75 IU ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET, PERGOVERIS 150 IU/75 IU ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ VE ÇÖZÜCÜ, 3 ADETProducts: LUVERIS 75 IU, LUVERIS FOR INJECTION 75 iu/vial (Revised formula)